Achilles Therapeutics is discontinuing its TIL-based cNeT program and closing its Phase I/IIa CHIRON and THETIS clinical trials The company's stock surged 31.7% in response to this announcement.

CHIRON and THETIS. What To Know: Achilles announced it will refocus its strategy to explore collaborations with third parties ...

Achilles Therapeutics (NASDAQ:ACHL) ADRs added ~42% in the premarket on Thursday after the U.K.-based biotech announced plans to explore strategic alternatives and close its CHIRON and THETIS ...

19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and THETIS clinical ...

and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its ...

Morningstar brands and products Company Portfolio ...

19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and THETIS clinical trials ...